Advanced Electron Beams, Inc
Oasys Water, Inc.

Two Flagship Companies -- Advanced Electron Beams and Oasys Water -- receive DOE Awards in the Industrial Energy Efficiency Grand Challenge

Two Flagship Companies -- Advanced Electron Beams and Oasys Water -- receive DOE Awards in the Industrial Energy Efficiency Grand Challenge

May 5, 2010

Advanced Electron Beams and Oasys Water have each received awards under the DOE's Industrial Energy Efficiency Grand Challenge. They are two of six Massachusetts companies so honored. The DOE press release is below, and contains links to details of all the wards.


DOE Announces Awardees for the Industrial Energy Efficiency Grand Challenge

Award winners to receive more than $13 million to develop transformational manufacturing processes and technologies

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program

April 14, 2010

Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate

CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc. (NASDAQ:BIIB), for the selection of the first humanized antibody development candidate from its ErbB3 program.

Agios Pharmaceuticals, Inc.

Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism

Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism

April 15, 2010

Partnership leverages transformational science at Agios and translational capabilities of Celgene to target areas of significant unmet medical need

Ze-gen, Inc.

Ze-gen Welcomes David Robertson As Vice President of Technology

Ze-gen Welcomes David Robertson As Vice President of Technology

April 28, 2010

BOSTON--(BUSINESS WIRE)-- Ze-gen, Inc., a leading developer and integrator of advanced gasification technology to convert waste streams into synthesis gas, today announced the addition of David Robertson to the Ze-gen team. Mr. Robertson is joining Ze-gen as Vice President of Technology.

Mr. Robertson joins Ze-gen after a 30 year career with BP plc. He will be leading the technology development, project deployment, and operations activities at Ze-gen as they progress commercialization of their gasification process.

Avedro, Inc.

Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device

Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device

April 20, 2010

The company prepares for immediate commercial launch throughout Europe and Asia

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. today announced its Vedera™ System for performing the Keraflex® procedure has received the European Union’s CE Mark. The CE Mark certifies the Vedera has met the EU’s health and safety standards and opens the door to commercialization across the European Economic Community and in other countries recognizing the CE Mark.

Joule Unlimited, Inc.

Solar Fuel Pioneered by Joule Named among World’s 10 Most Important Emerging Technologies

Solar Fuel Pioneered by Joule Named among World’s 10 Most Important Emerging Technologies

April 21, 2010

Breakthrough platform for direct conversion of sunlight into renewable diesel earns Joule a place among the prestigious Technology Review TR10 for 2010

Wall Street Journal Interview with Bob Weinberg, Co-founder of Flagship Ventures company Theracrine, on his Work in Understanding Cancer

Wall Street Journal Interview with Bob Weinberg, Co-founder of Flagship Ventures company Theracrine, on his Work in Understanding Cancer

April 13, 2010

Bob Weinberg, co-founder of Flagship Ventures company Theracrine, was quoted in the Wall Street Journal about his leading work in understanding the biology of metastasis. Flagship Ventures founded Theracrine with Bob Weinberg, as well as Joan Massague, Doug Hanahan, and Michael Rosenblatt in 2008 to develop drugs to treat metastasis by interrupting Malignant Plasticity.

AVEO Pharmaceuticals, Inc.

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies

March 24, 2009

Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America

AVEO Pharmaceuticals, Inc.

OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

July 21, 2009

MELVILLE, N.Y. and CAMBRIDGE, Mass.--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007. The alliance is anchored around developing molecular targeted therapies to target the underlying mechanisms of epithelial-mesenchymal transition (EMT) in cancer and to develop proprietary datasets of associated patient selection biomarkers to support OSI’s targeted medicine pipeline.

e-Dialog, Inc.

GSI Commerce to Acquire e-Dialog

GSI Commerce to Acquire e-Dialog

January 24, 2008

Acquisition Expands Size and Scope of GSI’s Interactive Marketing Services Capabilities in U.S. and Europe; e-Dialog to Operate as Stand-Alone Subsidiary